National Harbor, Md.—A long-term study designed to provide the definitive answer regarding taxane maintenance therapy for women with advanced ovarian cancer has found that the strategy failed to significantly improve overall survival (OS) over surveillance and was associated with significant adverse events (AEs), especially neurotoxicity.
“The lack of a demonstrable increase in OS, compounded by the neurotoxicity profile, pretty much takes taxanes out of the